Indonesian clinical practice guidelines for systemic and biologic agents for adults with plaque psoriasis

Novianto, Endi; Budianti, Windy; Fitri, Eyleny Meisyah; Wiryadi, Benny; Soebaryo, Retno Widowati; Pusponegoro, Erdina Hd; Effendi, Evita Halim; Rahmayunita, Githa; Irawan, Anis; Prakoeswa, Cita Rosita Sigit; Kariosentono, Harijono; Purnawan, Shafira; Debinta, Arlha

doi:10.19100/jdvi.v5i3.244

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients use methotrexate as systemic therapy (61.9%). This outcome is consistent with Indonesian treatment guidelines that prioritize methotrexate as the first line of psoriasis treatment [ 35 ]. Methotrexate is commonly recommended in international psoriasis guidelines due to its cost-effectiveness and safety [ 36 ].…”

Section: Discussionsupporting

confidence: 87%

Association between the severity of hard-to-treat psoriasis and the prevalence of metabolic syndrome: A hospital-based cross-sectional study in Jakarta, Indonesia

Evyana,

Novianto,

Budianti

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Psoriatic lesions on the scalp, face, intertriginous, genitals, palms/soles, and nails are often delay diagnosed, hard-to-treat, and cause disability. Metabolic syndrome (MetS) is one of the most frequent and significant comorbidities in psoriasis. Many studies have discovered a link between psoriasis and MetS, but none have specifically assessed the hard-to-treat psoriasis in Indonesian population. This is a multicenter study involving four dermatology referral hospitals to investigate the association between psoriasis severity that has hard-to-treat lesions with the prevalence of MetS in Jakarta, Indonesia. Data was collected from April to October 2022. The severity of 84 hard-to-treat psoriasis patients was measured by Psoriasis Area Severity Index (PASI) scores. The participants divided into PASI score >10 (severe) and ≤ 10 (mild-moderate) groups. MetS was identified based on the modified National Cholesterol Education Program Adult Treatment Panel III. MetS was found in 64.3% of patients. Patients with a PASI score>10 had a significantly higher risk of metabolic syndrome compared to those with a score ≤ 10 (78.6% vs 50%, OR 3.667; 95% CI 1.413–9.514; p = 0.006). The prevalence of hypertension (p = 0.028), low levels of high-density lipoprotein (HDL) cholesterol (p = 0.01), mean fasting blood sugar (p = 0.018), and triglyceride levels (p = 0.044) between the two groups differed significantly. This study found most frequent components of MetS were abdominal obesity, decreased levels of HDL cholesterol, hypertension, hyperglycemia, and hypertriglyceridemia respectively. Individuals with severe hard-to-treat psoriasis had a 3.67 times more likely to have MetS rather than the mild-moderate group.

show abstract

Section: Discussionsupporting

confidence: 87%

Association between the severity of hard-to-treat psoriasis and the prevalence of metabolic syndrome: A hospital-based cross-sectional study in Jakarta, Indonesia

Evyana,

Novianto,

Budianti

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…Biological systemic therapy has several advantages such as excellent therapeutic response (reaching PASI 90 or even 100), relatively safer, and minimal side effects compared to non-biological systemic therapy. In Indonesia, biologic agents are indicated for moderate to severe psoriasis cases with at least one of the following criteria: (1) adult patients who do not respond well to at least two standard systemic therapies such as cyclosporin A, methotrexate, or phototherapy, (2) intolerant or contraindicated to conventional systemic treatment (Novianto et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

“…Biologic agents are strictly contraindicated for pregnant or nursing women, children under the age of 18, and individuals with systemic diseases, particularly TB, hepatitis, HIV, cancer, or neurological disease (Novianto et al, 2021). Supporting tests, such as histology, anti-streptolysin O (ASTO) titers, albumin, fat profiles, uric acid, full blood counts, total urine, liver function tests (AST/ALT), renal function tests (BUN/SC ratio), and serum electrolytes, should be performed before treatment.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of secukinumab in severe plaque psoriasis

Damayanti

Prakoeswa

Anggraeni

et al. 2022

ijhs

View full text Add to dashboard Cite

Psoriasis is a persistent, chronic condition that manifests on the skin, joints, and other visible places that compromises the quality of life. The vast understanding of the pathophysiology of psoriasis has led to a rise in the use of biological therapy in treating psoriasis in recent years. A 48-year-old woman with severe plaque psoriasis was previously treated with methotrexate and phototherapy for 3 months, however, the treatment showed no significant improvement. The patient was then treated with a biological agent, namely secukinumab, with a dose of 150 mg weekly for 5 weeks followed by one dose a month later. The symptoms were improved considerably after 10 weeks of observation, which indicated by the decrease in Psoriasis Area Severity Index (PASI) score and the Dermatology Life Quality Index (DLQI) score. There was no significant side effect during the observation. This case showed that secukinumab therapy at a dose of 150 mg can successfully treat severe plaque psoriasis patient.

show abstract

Indonesian clinical practice guidelines for systemic and biologic agents for adults with plaque psoriasis

Cited by 2 publications

References 0 publications

Association between the severity of hard-to-treat psoriasis and the prevalence of metabolic syndrome: A hospital-based cross-sectional study in Jakarta, Indonesia

Association between the severity of hard-to-treat psoriasis and the prevalence of metabolic syndrome: A hospital-based cross-sectional study in Jakarta, Indonesia

Successful treatment of secukinumab in severe plaque psoriasis

Contact Info

Product

Resources

About